Literature DB >> 11514542

Interferon-kappa, a novel type I interferon expressed in human keratinocytes.

D W LaFleur1, B Nardelli, T Tsareva, D Mather, P Feng, M Semenuk, K Taylor, M Buergin, D Chinchilla, V Roshke, G Chen, S M Ruben, P M Pitha, T A Coleman, P A Moore.   

Abstract

High throughput cDNA sequencing has led to the identification of interferon-kappa, a novel subclass of type I interferon that displays approximately 30% homology to other family members. Interferon-kappa consists of 207 amino acids, including a 27-amino acid signal peptide and a series of cysteines conserved in type I interferons. The gene encoding interferon-kappa is located on the short arm of chromosome 9 adjacent to the type I interferon gene cluster and is selectively expressed in epidermal keratinocytes. Expression of interferon-kappa is significantly enhanced in keratinocytes upon viral infection, upon exposure to double-stranded RNA, or upon treatment with either interferon-gamma or interferon-beta. Administration of interferon-kappa recombinant protein imparts cellular protection against viral infection in a species-specific manner. Interferon-kappa activates the interferon-stimulated response element signaling pathway and a panel of genes similar to those regulated by other type I interferons including anti-viral mediators and transcriptional regulators. An antibody that neutralizes the type I interferon receptor completely blocks interferon-kappa signaling, demonstrating that interferon-kappa utilizes the same receptor as other type I interferons. Interferon-kappa therefore defines a novel subclass of type I interferon that is expressed in keratinocytes and expands the repertoire of known proteins mediating host defense.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514542     DOI: 10.1074/jbc.M102502200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  91 in total

1.  Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model.

Authors:  Taisuke Ito; Natsuho Ito; Albrecht Bettermann; Yoshiki Tokura; Masahiro Takigawa; Ralf Paus
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

2.  Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.

Authors:  Raj Deonarain; Amit Verma; Andrew C G Porter; Dirk R Gewert; Leonidas C Platanias; Eleanor N Fish
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

Review 3.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 4.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

5.  Blockade of virus infection by human CD4+ T cells via a cytokine relay network.

Authors:  Ann M Davis; Kristan A Hagan; Loderick A Matthews; Gagan Bajwa; Michelle A Gill; Michael Gale; J David Farrar
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

6.  Standardization of human IL-29 (IFN-λ1): establishment of a World Health Organization international reference reagent for IL-29 (IFN-λ1).

Authors:  Anthony Meager; Alan Heath; Paula Dilger; Kathryn Zoon; Meenu Wadhwa
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

7.  Characterization of the murine alpha interferon gene family.

Authors:  Vincent van Pesch; Hanane Lanaya; Jean-Christophe Renauld; Thomas Michiels
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Interferon Kappa Inhibits Human Papillomavirus 31 Transcription by Inducing Sp100 Proteins.

Authors:  Christina Habiger; Günter Jäger; Michael Walter; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

9.  Characterization of the bovine type I IFN locus: rearrangements, expansions, and novel subfamilies.

Authors:  Angela M Walker; R Michael Roberts
Journal:  BMC Genomics       Date:  2009-04-24       Impact factor: 3.969

10.  Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.

Authors:  Reinhard Dummer; Joanna Mangana
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.